NAD+ is the master coenzyme of cellular energy metabolism, DNA repair, and longevity signaling. Men lose approximately 50% of their NAD+ levels between ages 40 and 60 — a decline linked to reduced energy, impaired recovery, metabolic dysfunction, and accelerated aging. NAD+ supplementation via IV, SubQ, or oral precursors (NMN/NR) is one of the most evidence-supported longevity interventions available.
Men's higher muscle mass and metabolic rate means they consume NAD+ faster than women — making age-related NAD+ decline particularly impactful. The consequences compound: reduced mitochondrial efficiency impairs athletic performance and recovery; declining SIRT1 activity reduces testosterone synthesis efficiency; impaired PARP-1 activity increases genomic instability. NAD+ supplementation addresses all three pathways simultaneously.
NAD+ is the primary electron carrier in the mitochondrial electron transport chain. As NAD+ declines with age, mitochondrial efficiency drops — producing less ATP per unit of substrate. Restoring NAD+ levels directly improves cellular energy production, which men experience as improved stamina, reduced fatigue, and faster recovery.
Sirtuins are NAD+-dependent deacetylases that regulate gene expression, DNA repair, inflammation, and metabolic homeostasis. SIRT1 activates PGC-1α (mitochondrial biogenesis), SIRT3 optimizes mitochondrial function, and SIRT6 regulates DNA repair and telomere maintenance. NAD+ supplementation activates the full sirtuin network.
PARP-1 (poly ADP-ribose polymerase) consumes NAD+ to repair DNA strand breaks. In men with high oxidative stress (from exercise, environmental toxins, or aging), PARP-1 activity depletes NAD+ rapidly. Supplementing NAD+ ensures adequate substrate for PARP-1 activity, maintaining genomic integrity and reducing cancer risk.
| Form | Dose | Frequency | Notes |
|---|---|---|---|
| IV Infusion | 250–500 mg per session | 1–3x per week | Fastest cellular NAD+ elevation. Requires clinical setting. |
| IV Infusion (loading) | 500–1000 mg per session | Daily for 4–10 days | Loading protocol for severe deficiency or addiction recovery. |
| SubQ Injection | 25–100 mg per injection | Daily or 3–5x per week | Practical for home use. Slower onset than IV. |
| Oral NMN | 250–1000 mg/day | Once daily, morning | Most studied oral precursor. Lower bioavailability than IV/SubQ. |
| Oral NR | 250–500 mg/day | Once or twice daily | Well-tolerated. Comparable to NMN in human trials. |
| Outcome | Evidence | Mechanism | Timeline |
|---|---|---|---|
| Cellular energy (ATP) | Strong (human trials) | Mitochondrial ETC optimization | 24–72 hours (IV) |
| Exercise performance | Moderate (human trials) | Improved VO2max, muscle NAD+ | 4–8 weeks |
| Cognitive function | Moderate | Neuronal NAD+, SIRT1 activation | 2–4 weeks |
| DNA repair capacity | Strong (in vitro + rodent) | PARP-1 substrate availability | 4–12 weeks |
| Metabolic health | Moderate (human trials) | SIRT1/AMPK/PGC-1α axis | 8–16 weeks |
| Testosterone support | Indirect/emerging | Leydig cell mitochondrial function | 8–16 weeks |
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activation. In men, NAD+ levels decline approximately 50% between ages 40 and 60, contributing to reduced energy, impaired mitochondrial function, slower recovery, and age-related metabolic decline. NAD+ supplementation is researched for restoring cellular energy, improving exercise performance, supporting testosterone production, and activating longevity pathways.
IV NAD+ infusions: 250–1000 mg per session, typically 1–3 times per week. SubQ NAD+: 25–100 mg per injection, daily or several times per week. Oral precursors (NMN/NR): 250–1000 mg/day orally — less bioavailable but more convenient. For men seeking systemic anti-aging and energy benefits, IV or SubQ protocols produce the most measurable NAD+ elevation. Oral precursors are suitable for maintenance.
NAD+ does not directly stimulate testosterone production. However, NAD+-dependent sirtuins (SIRT1, SIRT3) regulate steroidogenesis enzymes in Leydig cells. NAD+ also supports mitochondrial function in testicular tissue — mitochondria are essential for testosterone synthesis. Men with metabolic syndrome or chronic fatigue (conditions associated with low NAD+) may see indirect testosterone improvements as cellular energy metabolism normalizes.
Energy improvements are typically the first effect, often reported within 24–48 hours of IV infusion. Improved cognitive clarity and reduced brain fog appear within 1–2 weeks of consistent supplementation. Measurable improvements in exercise performance and recovery are typically observed at 4–8 weeks. Longevity biomarkers (telomere length, DNA repair capacity) require 3–6 months of consistent supplementation to assess.
IV NAD+ produces the fastest and most pronounced cellular NAD+ elevation — bypassing gut absorption entirely. SubQ NAD+ is more practical for ongoing use. NMN (nicotinamide mononucleotide) is the most studied oral precursor, with evidence for direct NAD+ elevation in human trials. NR (nicotinamide riboside) is also well-studied. For men seeking maximum effect, IV or SubQ protocols are preferred; oral NMN is suitable for maintenance between IV sessions.
Yes — NAD+ is commonly combined with other longevity compounds. The most studied combinations for men are: NAD+ + Epithalon (telomere support + NAD+ for comprehensive anti-aging), NAD+ + MOTS-c (mitochondrial optimization — MOTS-c activates AMPK while NAD+ fuels the mitochondrial electron transport chain), and NAD+ + Glutathione (antioxidant support alongside NAD+ energy metabolism). These combinations are additive rather than synergistic.
IV NAD+ infusions commonly produce flushing, chest tightness, and nausea during the infusion — these are dose-rate dependent and resolve by slowing the infusion rate. SubQ NAD+ has a milder side effect profile: mild injection site reactions and occasional flushing. Oral NMN/NR are generally well-tolerated. No significant hormonal, androgenic, or estrogenic side effects have been documented.
IV NAD+ produces the most rapid and pronounced cellular NAD+ elevation, with effects typically felt within hours. For men with significant energy deficits, cognitive impairment, or post-illness recovery needs, IV therapy provides the fastest results. For general longevity and maintenance, oral NMN or SubQ protocols are more cost-effective. The decision depends on baseline NAD+ deficit severity and desired speed of results.
Third-party COA verified. ≥99% purity. Use code HEALTH for 15% off.
View NAD+ at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.